NZOZ Medica Jerzy Cygler
- Address
- Ul. Zeglarska 6/u3, 11-500 Giżycko, Poland
Cardiovascular Diseases
Clinical research at NZOZ Medica Jerzy Cygler includes a strong focus on cardiology and cardiovascular diseases, with studies aimed at lowering the risk of serious events such as heart attack and stroke, and improving care for people with high-risk heart conditions.
- Testing new approaches to reduce coronary heart disease events in people with elevated cardiovascular risk
- Studying treatments for atherosclerotic cardiovascular disease and elevated lipoprotein(a)
- Evaluating therapies for hypertension and broader cardiovascular risk control
These trials are designed to assess whether newer therapies can better prevent major cardiovascular complications and support long-term risk reduction in patients with established disease or significant risk factors.
Respiratory Tract Diseases
The site also conducts studies in respiratory tract diseases, especially chronic obstructive pulmonary disease and asthma, with research focused on improving breathing symptoms, reducing flare-ups, and supporting better daily lung function.
- Evaluating treatments for COPD to improve lung function and reduce exacerbations
- Investigating new options for eosinophilic asthma and severe eosinophilic asthma
- Assessing add-on therapies aimed at better control of chronic respiratory symptoms
These trials explore whether emerging respiratory therapies can offer more effective symptom control and fewer disease worsening episodes for patients with persistent airway disease.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic diseases at this hospital/clinic site includes studies linked to lipid-related cardiovascular risk, reflecting interest in how metabolic factors influence long-term heart health.
- Examining treatments that target lipoprotein(a) as a contributor to cardiovascular risk
- Assessing lipid-lowering strategies for people with high cardiovascular risk
- Studying therapies intended to improve prevention in patients with metabolic risk profiles
Overall, this area of research aims to determine whether better control of metabolic risk markers can help prevent serious cardiovascular outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Amgen Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Areteia Therapeutics Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ Medica Jerzy Cygler
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study | Amgen Inc. | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexpramipexole Dihydrochloride Monohydrate | 3 | Unknown | 2023-04-25 | 2024-10-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.